Home / Health / Revolutionary CAR-T Advances Offer Hope for Solid Cancers
Revolutionary CAR-T Advances Offer Hope for Solid Cancers
24 Feb
Summary
- CAR001 uses a unique γδ T-cell platform for solid tumors.
- It targets HLA-G and releases anti-PD-L1 within the tumor.
- One patient showed significant tumor reduction and functional recovery.
Cancer immunotherapy is advancing with CAR-T cell therapy, which has revolutionized blood cancer treatment but faced limitations with solid tumors. These solid tumors account for over 90% of cancer cases and present unique biological challenges such as poor immune infiltration and immunosuppression.
A new therapy, CAR001, developed through collaboration with Ever Supreme BioTechnology in Taiwan, employs a distinct γδ T-cell platform. This design allows for MHC-independent tumor recognition, making it broadly applicable. CAR001 incorporates a dual mechanism: it targets HLA-G, an immune checkpoint, and locally secretes an anti-PD-L1 bispecific engager.
This integrated strategy aims to directly kill tumor cells and activate local immune responses. Clinical studies are evaluating CAR001, with one patient experiencing an 86.02% reduction in tumor size and improved speech and communication. Reductions in circulating tumor cells were also observed.
The future of cell therapy may involve in vivo CAR-T, where immune cells are programmed within the patient. This approach, also being developed with Ever Supreme BioTechnology, could simplify treatment, reduce costs, and increase accessibility for advanced immunotherapy.
